Insignia (hip implant)

Main article: Endoprostheses

2022: Market Entry

On March 22, 2022, Stryker announced the launch of the production of the hip implant Insignia. Bioimplant is intended for procedures of total hip and hemiarthroplasty endoprosthetics, which will allow to optimize operations on patients and facilitate implantation by the surgeon in musculoskeletal approaches.

Insignia is compatible with Stryker's Mako SmartRobotics platform, which uses software () ON Total Hip 4.1. The platform allows surgeons to use data from a 3D plan based on to computed tomography determine the unique anatomy of each patient, according to a press release.

Stryker released a hip implant inserted by a robot surgeon

Surgery to replace the joint with an implant is usually performed to relieve pain in arthritis or for some hip fractures. Complete hip endoprosthesis consists of replacing both the cotyloid cavity and the femoral head, while hemiarthroplasty usually replaces only the hip head.

{{quote 'Insignia joins Stryker's family of market-leading hip legs to complement our core hip portfolio. Compatible with the Mako SmartRobotics system, Insignia provides tailored fit, functionality and flexibility, allowing surgeons to further improve patient outcomes, said Stryker Vice President and CEO of Hip Katherine Truppi. }} The platform includes a Tri-Stage with three different tooth geometries, as well as a collar length specific for each size and a series of femoral displacements to improve fit and function inserted by a robot surgeon. Insignia short rod length and distal relief, this is necessary in order to facilitate lateralization and administration in muscle-sparing approaches.

The company reported that Insignia complements its advanced digital health offerings, including expanding the capabilities of Mako's robotic surgical platform.^[1]

Notes